Form 4 Filing for MoonLake Immunotherapeutics

This filing concerns a Form 4 filed by Kristian Reich, Chief Scientific Officer of MoonLake Immunotherapeutics. On July 15, 2026, Reich executed a Rule 10b5-1 trading plan, resulting in the sale of 16,105 shares of Class A ordinary shares at a weighted average price of $20.01 per share. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.04. Following this transaction, Reich directly owns 35,389 shares. Additionally, the filing notes that Dr. Reich may be deemed the indirect beneficial owner of shares held by JeruCON Beratungsgesellschaft mbH.